https://clinicaltrials.gov/ct2/show/NCT04129775?type=Intr&cond=Hearing+Loss&lupd_s=10%2F03%2F2019&lupd_d=14&sort=nwst
Condition : Sensorineural Hearing Loss
Interventions : Drug: OTO-413; Drug: Placebo
Sponsor : Otonomy, Inc.
Recruiting
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
NCT04129775
Thu, 17 Oct 2019 12:00:00 EDT
Last Update Posted: 10/17/19 08:21AM
https://clinicaltrials.gov/ct2/show/NCT04129775
OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
Updated: September 14, 2020
Active, not recruiting
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2020